UBS Group’s WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS WX Stock Holding History

UBS Group’s Portfolio WX Stock Details WX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-35,326	Closed	-$1.53M	–	8870
2015 Q3	$1.53M	Sell	35,326 -1,646	-4%	-$69.5K	﹤0.01%	2985
2015 Q2	$1.56M	Sell	36,972 -32,166	-47%	-$1.36M	﹤0.01%	3210
2015 Q1	$2.68M	Buy	69,138 +2,083	+3%	+$80.2K	﹤0.01%	2657
2014 Q4	$2.26M	Buy	+67,055	New	+$2.37M	﹤0.01%	2785

Other funds holding WX

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

CCS

Crosspoint Capital Strategies Orinda, California $50.4M AUM 15.37% 1-Year Est. Return

UBS Group's WX Position: Q4 2015 in Review

UBS Group sold out of WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) in Q4 2015, closing a stake of 35,326 shares — an estimated $1.53M sold.

UBS Group first reported a position in WX in Q4 2014 and held it in 4 quarters. The position peaked at $2.68M in Q1 2015. 2 funds tracked by Wall St. Rank hold WX as of Q4 2015.

UBS Group reported no remaining WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position as of Q4 2015 after selling out during the quarter.
UBS Group sold 35,326 WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS shares in Q4 2015, an estimated $1.53M.
UBS Group first reported a position in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS in Q4 2014 and held it in 4 quarters.
UBS Group's WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position peaked at $2.68M in Q1 2015.
2 funds tracked by Wall St. Rank held WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS as of Q4 2015.

Based on UBS Group's 13F filing for Q4 2015, filed 16 Feb 2016.